SCHEMBL773455

SCHEMBL773455

O=c1[nH]cc([C@@H]2O[C@H](CO)C(O)C2F)c(=O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDA P32320 1/20 0.39
PNP P00491 5/20 0.35
UMPS P11172 1/20 0.34
PYGM P11217 3/20 0.34
ATM Q13315 1/20 0.34
MAPT P10636 3/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
SLC28A1 O00337 1/20 0.33
SLC28A2 O43868 1/20 0.33
SLC29A1 Q99808 1/20 0.33
SLC28A3 Q9HAS3 1/20 0.33
LMNA P02545 1/20 0.33
CYP19A1 P11511 1/20 0.33
TSHR P16473 1/20 0.33
THPO P40225 1/20 0.33
MTOR P42345 1/20 0.33
HTT P42858 1/20 0.33
HBB P68871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15216151 1.00 CDA (0.39) CDAPNPUMPSPYGMATM
SCHEMBL767735 1.00 CDA (0.39) CDAPNPUMPSPYGMATM
SCHEMBL767738 0.88 OGA (0.34) PNPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL16943073 0.88 OGA (0.34) PNPMAPTALDH1A1GAASMN1; SMN2
SCHEMBL14791302 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT
SCHEMBL17329460 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT
SCHEMBL767777 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT
SCHEMBL15803217 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT
SCHEMBL21847661 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT
SCHEMBL10226283 0.87 PNP (0.44) PNPUMPSPYGMATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071641-A1 NUCLEIC ACID CHEMICAL MODIFICATIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-03-22 US disclosed
US-20110130440-A1 NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
WO-2010101951-A1 NUCLEIC ACID CHEMICAL MODIFICATIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130440-A1 NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF NSUN2, RNMT, RNGTT CDA 90/4885PNP 115/4885UMPS 267/4885
US-20120071641-A1 NUCLEIC ACID CHEMICAL MODIFICATIONS NSUN2, RNMT, NSUN3 CDA 277/4885PNP 299/4885UMPS 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.